Brokerages Set Omnicell, Inc. (NASDAQ:OMCL) Price Target at $46.71

Omnicell, Inc. (NASDAQ:OMCL) has earned an average recommendation of “Hold” from the eight research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $46.7143.

A number of equities analysts have weighed in on the company. Wells Fargo & Company boosted their price objective on Omnicell from $37.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, July 21st. Weiss Ratings reissued a “sell (d+)” rating on shares of Omnicell in a research note on Saturday, September 27th. Wall Street Zen cut Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 9th. Finally, Piper Sandler cut their target price on Omnicell from $57.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 11th.

Insider Buying and Selling

In other Omnicell news, EVP Corey J. Manley sold 3,880 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $33.25, for a total value of $129,010.00. Following the completion of the transaction, the executive vice president owned 110,653 shares in the company, valued at $3,679,212.25. The trade was a 3.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 2.52% of the stock is owned by company insiders.

Hedge Funds Weigh In On Omnicell

Institutional investors have recently modified their holdings of the business. Thrivent Financial for Lutherans lifted its holdings in shares of Omnicell by 1.2% during the second quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock worth $1,013,000 after purchasing an additional 424 shares during the period. Liontrust Investment Partners LLP boosted its stake in shares of Omnicell by 81.2% during the 2nd quarter. Liontrust Investment Partners LLP now owns 318,284 shares of the company’s stock worth $9,358,000 after purchasing an additional 142,629 shares during the last quarter. Public Sector Pension Investment Board boosted its position in Omnicell by 8.7% during the second quarter. Public Sector Pension Investment Board now owns 159,658 shares of the company’s stock worth $4,694,000 after acquiring an additional 12,742 shares during the last quarter. Headlands Technologies LLC boosted its holdings in shares of Omnicell by 1,865.0% during the second quarter. Headlands Technologies LLC now owns 18,137 shares of the company’s stock worth $533,000 after purchasing an additional 17,214 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co boosted its stake in Omnicell by 3.2% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 53,233 shares of the company’s stock worth $1,566,000 after buying an additional 1,638 shares during the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Stock Up 3.2%

Shares of OMCL opened at $30.95 on Tuesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. Omnicell has a one year low of $22.66 and a one year high of $55.74. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of 61.90, a PEG ratio of 6.76 and a beta of 0.88. The stock has a 50 day moving average price of $31.51 and a 200 day moving average price of $30.57.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The firm had revenue of $290.56 million during the quarter, compared to the consensus estimate of $275.57 million. During the same period in the prior year, the company earned $0.51 EPS. The firm’s revenue was up 5.0% compared to the same quarter last year. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Equities research analysts forecast that Omnicell will post 1.09 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.